Leuner K, Müller W E
Department of Pharmacology, Biocenter, Goethe University, Frankfurt, Germany.
Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S15-20. doi: 10.1055/s-2006-931484.
Since the mid of the 1960s, striking similarities between the psychosis seen in subjects taking high doses of amphetamines and the symptoms of patients with paranoid schizophrenia have been noted and placed in the context of increased catecholaminergic neurotransmission as a fundamental cause underlying major symptoms of the disease. Subsequent studies emphasized the contribution of central dopaminergic mechanisms for at least several psychotic symptoms of schizophrenia. The most compelling pharmacological data to support the developing "dopamine hypothesis of schizophrenia" originated from the clear relationship between antipsychotic drug efficacy and affinity for D2-like dopamine receptors strongly indicating D2-antagonism as major if not exclusive mechanism of antipsychotic drug action. Accordingly, in this review we focus on the neuropharmacology of the dopaminergic system in our brain with special emphasis on the dopaminergic synapse.
自20世纪60年代中期以来,人们注意到服用高剂量苯丙胺的受试者所出现的精神病症状与偏执型精神分裂症患者的症状之间存在惊人的相似之处,并将其置于儿茶酚胺能神经传递增加的背景下,认为这是该疾病主要症状的根本原因。随后的研究强调了中枢多巴胺能机制在精神分裂症至少几种精神病症状中的作用。支持正在形成的“精神分裂症多巴胺假说”的最有说服力的药理学数据,源于抗精神病药物疗效与对D2样多巴胺受体的亲和力之间的明确关系,这有力地表明D2拮抗作用是抗精神病药物作用的主要(如果不是唯一的)机制。因此,在本综述中,我们将重点关注大脑中多巴胺能系统的神经药理学,特别强调多巴胺能突触。